Literature DB >> 17696616

Treatment of critical limb ischemia using ultrasound-enhanced thrombolysis (PARES Trial): final results.

Christian Wissgott1, André Richter, Peter Kamusella, Hermann J Steinkamp.   

Abstract

PURPOSE: To evaluate the safety and performance of ultrasound-enhanced thrombolysis in the treatment of acute thrombotic or embolic occlusion of the lower limb arteries.
METHODS: From April 2005 to July 2006, 25 patients (15 men; mean age 64.1 years, range 37-82) presenting with acute (<14 days old) occlusions of the lower limb arteries were treated with local thrombolysis [recombinant tissue plasminogen activator (rtPA)] in a dosage of 1.0 mg/h using the EKOS Lysus Peripheral Catheter System with an ultrasound core. No bolus injection of rtPA was given. The mean occlusion length was 25.1 cm (range 2-70).
RESULTS: The technical success rate was 100%. Total clot removal was achieved in 22 (88%) patients after 16.9 hours (range 5-24) using a mean 17 mg (range 5-25) of rtPA. In 8 cases, total clot removal of the main lesion was achieved after 6 hours (6 mg of rtPA). In 1 patient, lysis was stopped after 2.5 hours because of bleeding due a dislocation of the introducer sheath. In 2 cases, total clot removal could not be achieved; these patients were successfully treated with thromboaspiration. At the 1-month follow-up, the treated vessel was still patent in 20 patients. Two reocclusions occurred; 1 was treated with a bypass graft and the other with conservative therapy. There were no cases of amputation or death during follow-up. There were no side effects related to rtPA or the catheter system.
CONCLUSION: This study demonstrates that local lysis of acute arterial occlusions using the Lysus Peripheral Catheter System is safe and effective. Blood flow is restored quickly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696616     DOI: 10.1177/152660280701400402

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  7 in total

Review 1.  Cardiovascular therapeutic uses of targeted ultrasound contrast agents.

Authors:  Susan T Laing; David D McPherson
Journal:  Cardiovasc Res       Date:  2009-07-06       Impact factor: 10.787

2.  Ultrasound-Enhanced Thrombolysis: EKOS EndoWave Infusion Catheter System.

Authors:  Charles A Owens
Journal:  Semin Intervent Radiol       Date:  2008-03       Impact factor: 1.513

3.  Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model--brief report.

Authors:  Susan T Laing; Melanie Moody; Beverly Smulevitz; Hyunggun Kim; Patrick Kee; Shaoling Huang; Christy K Holland; David D McPherson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-24       Impact factor: 8.311

4.  Minimally invasive evacuation of spontaneous intracerebral hemorrhage using sonothrombolysis.

Authors:  David W Newell; M Mohsin Shah; Robert Wilcox; Douglas R Hansmann; Erik Melnychuk; John Muschelli; Daniel F Hanley
Journal:  J Neurosurg       Date:  2011-06-10       Impact factor: 5.115

5.  Tissue plasminogen activator concentration dependence of 120 kHz ultrasound-enhanced thrombolysis.

Authors:  George J Shaw; Jason M Meunier; Christopher J Lindsell; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2008-05-12       Impact factor: 2.998

6.  Dutch randomized trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale.

Authors:  A Marjolein Schrijver; Michel M P J Reijnen; Jacques A van Oostayen; Rudolf P J Tutein Nolthenius; Pieter H M van der Valk; Arjan W J Hoksbergen; Rutger J Lely; Bram Fioole; Dammis Vroegindeweij; Marc van Leersum; Jean-Paul P M de Vries
Journal:  Trials       Date:  2011-01-23       Impact factor: 2.279

7.  One of the most urgent vascular circumstances: Acute limb ischemia.

Authors:  Rezzan D Acar; Muslum Sahin; Cevat Kirma
Journal:  SAGE Open Med       Date:  2013-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.